In addition, recent studies have demonstrated the therapeutic efficacy of anti–CD155 blocking antibodies in preclinical tumor models, either as monotherapy or in combination with other immunotherapies such as CD33 CAR-T cells or PD-1 blockade, further supporting CD155 as a viable immunotherapeutic target (43, 44). This evidence concerns the gene PVR and neoplasm.